Silexion Therapeutics LTD (SLXNW)
NASDAQ: SLXNW
· Real-Time Price · USD
0.07
0.00 (1.01%)
At close: Jun 09, 2025, 9:30 AM
Silexion Therapeutics LTD Income Statement
Financials in USD. Fiscal
year is
January - December.
| Fiscal Year | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 |
| Period Ending | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 |
Revenue | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost of Revenue | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Gross Profit | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Operating Income | n/a | -1.9M | -8.04M | -1.39M | n/a | -1.73M | -731K | -155.47K | -436.73K | -488.11K | -237K | -156.99K | -350.24K | -433.4K | n/a | -195.06K | -92.65K |
Interest Income | n/a | n/a | n/a | 6K | 19K | 33K | 42K | 318K | 745.04K | 992.92K | 520.02K | 163.34K | 9.39K | 2.18K | 1.77K | 1.75K | 676.00 |
Pretax Income | 1.74M | -1.75M | -11.86M | -110.58K | -1.42M | -1.67M | -803K | 162.95K | 313.19K | 494.41K | 292.58K | 42.69K | -245.66K | -241.77K | -223.91K | -191.79K | -97.75K |
Net Income | 1.74M | -1.75M | -11.85M | -1.47M | -1.37M | -1.73M | -787K | 162.95K | 313.19K | 494.41K | 292.58K | 42.69K | -245.66K | -241.77K | -223.91K | -191.79K | -97.75K |
Selling & General & Admin | 1.06M | 1.04M | 4.82M | 619K | 281K | 465K | 186K | 155.47K | 436.73K | 488.11K | 237K | 156.99K | 350.24K | 433.4K | n/a | 195.06K | 92.65K |
Research & Development | 590K | 871K | 3.22M | 766K | 961K | 1.26M | 535K | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Other Expenses | n/a | -8K | n/a | n/a | 8K | 6K | 10K | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Operating Expenses | 1.65M | 1.9M | 8.04M | 1.39M | 1.25M | 1.73M | 731K | 155.47K | 436.73K | 488.11K | 237K | 156.99K | 350.24K | 433.4K | n/a | 195.06K | 92.65K |
Interest Expense | n/a | n/a | n/a | 2K | n/a | -43K | 45K | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | n/a | 1.9M | 8.04M | 1.39M | 1.25M | 1.73M | 731K | -155.47K | -436.73K | -488.11K | -237K | -156.99K | -350.24K | -433.4K | n/a | -195.06K | -92.65K |
Income Tax Expense | n/a | 1K | 2K | -2K | 5K | 6K | 6K | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Shares Outstanding (Basic) | 6.78M | 1.85M | 647.57K | 430K | 430K | 430K | 552.77K | 660.51K | 1.21M | 1.65M | 1.65M | 1.65M | 1.65M | 1.65M | 1.65M | 1.65M | 1.65M |
Shares Outstanding (Diluted) | 6.78M | 1.85M | 647.57K | 430K | 430K | 430K | 552.77K | 660.51K | 1.21M | 1.65M | 1.65M | 1.65M | 1.65M | 1.65M | 1.65M | 1.65M | 1.65M |
EPS (Basic) | 0.26 | -2.7 | -18.31 | -0.26 | -0.47 | -0.67 | 0.13 | 0.25 | 0.26 | 0.30 | 0.18 | 0.03 | -0.15 | -0.15 | -0.14 | -0.12 | -0.06 |
EPS (Diluted) | 0.26 | -2.7 | -18.31 | -0.26 | -0.47 | -0.67 | 0.13 | 0.03 | 0.26 | 0.03 | 0.02 | 0.03 | -0.15 | -0.02 | -0.14 | -0.12 | -0.06 |
EBITDA | n/a | -1.75M | -8.01M | -1.48M | -1.24M | -1.72M | -721K | 162.95K | 313.19K | 494.41K | 292.58K | 42.69K | -245.66K | -241.77K | -223.9K | -191.79K | -97.75K |
EBIT | n/a | -5.83M | -8.04M | -1.49M | -1.25M | -1.73M | -731K | 162.95K | 313.19K | 494.41K | 292.58K | 42.69K | -245.66K | -241.77K | -223.9K | -191.79K | -97.75K |
Depreciation & Amortization | n/a | -30K | 22K | 7K | 8K | 6K | 10K | 318.42K | 749.92K | 982.52K | 529.58K | 199.69K | 104.58K | 191.63K | n/a | 3.27K | -5.1K |